SGS partners with theblood to develop menstrual blood diagnostics

SGS has partnered with Berlin start-up theblood to support development and validation of women's health diagnostics using menstrual blood, with SGS providing quality assurance and bioanalytical expertise.

SGS has entered a partnership with Berlin-based health tech start-up theblood to explore menstrual blood as a diagnostic matrix, the announcement dated February 12, 2026, reports. The collaboration aims to create a scientific and regulatory foundation for non-invasive, female-specific diagnostics. SGS will act as an independent quality and validation partner and contribute global pharma expertise in bioanalytical sciences. Theblood focuses on systematic study of menstrual blood to address data gaps in women's health. Key facts: - SGS, a global testing, inspection and certification company, announced a partnership with Berlin-based start-up theblood. - The collaboration centers on menstrual blood as a non-invasive biological matrix for women's health diagnostics. - SGS will provide quality assurance, validation support and bioanalytical expertise to accompany theblood's development work. - The article notes menstrual blood contains biomarkers linked to conditions such as endometriosis and polycystic ovary syndrome (PCOS) and other fertility-related conditions. - Representatives from both organizations emphasized the need for scientific rigor, reproducibility and regulatory awareness to build trust in new diagnostic approaches. Summary: The partnership is positioned to advance research and validation of menstrual blood–based diagnostics and to embed quality and regulatory considerations early in development. The work is intended to support generation of accurate and reproducible evidence for clinicians, regulators and patients. Timeline and specific validation steps were not detailed in the announcement and remain undetermined at this time.